Glycans/CLRs are emerging as promising immune checkpoints to exploit in order to reshape potent antitumor immunity and inhibit immunosuppressive circuits triggered by aberrant tumor glycosylation patterns, rescuing DCs from tumor’ hijacking and improving clinical success in cancer patients. Here, LARS1 is linked to neoplasm.